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Abstract
Background: The standard uptake value (SUV) approach in oncological positron emission tomography has known
shortcomings, all of which affect the reliability of the SUV as a surrogate of the targeted quantity, the metabolic rate of
[18F]fluorodeoxyglucose (FDG), Km. Among the shortcomings are time dependence, susceptibility to errors in scanner
and dose calibration, insufficient correlation between systemic distribution volume and body weight, and,
consequentially, residual inter-study variability of the arterial input function (AIF) despite SUV normalization. Especially
the latter turns out to be a crucial factor adversely affecting the correlation between SUV and Km and causing
inter-study variations of tumor SUVs that do not reflect actual changes of the metabolic uptake rate. In this work, we
propose to replace tumor SUV by the tumor-to-blood standard uptake ratio (SUR) in order to distinctly improve the
linear correlation with Km.
Methods: Assuming irreversible FDG kinetics, SUR can be expected to exhibit a much better linear correlation to Km
than SUV. The theoretical derivation for this prediction is given and evaluated in a group of nine patients with liver
metastases of colorectal cancer for which 15 fully dynamic investigations were available and Km could thus be derived
from conventional Patlak analysis.
Results: For any fixed time point T at sufficiently late times post injection, the Patlak equation predicts a linear
correlation between SUR and Km under the following assumptions: (1) approximate shape invariance (but arbitrary
scale) of the AIF across scans/patients and (2) low variability of the apparent distribution volume Vr (the intercept of
the Patlak Plot). This prediction - and validity of the underlying assumptions - has been verified in the investigated
patient group. Replacing tumor SUVs by SURs does improve the linear correlation of the respective parameter with Km
from r = 0.61 to r = 0.98.
Conclusions: SUR is an easily measurable parameter that is highly correlated to Km. In this respect, it is clearly
superior to SUV. Therefore, SUR should be seriously considered as a drop-in replacement for SUV-based approaches.
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Background
Today, in the clinical oncological setting, the standard
uptake value (SUV, g/ml), defined as the tracer concentra-
tion at a certain time point normalized to injected dose
per unit body weight is essentially the only means for
quantitative evaluation of [18F]fluorodeoxyglucose (FDG)
positron emission tomography (PET). While it is per-
fectly possible to quantify the actually targeted parameter,
namely the absolute metabolic rate of glucose consump-
tion (or, rather, the rate of irreversible FDG accumulation,
Km), the conventional approaches such as the Patlak plot
[1,2] require to a varying degree dynamic imaging and
also determination of the full arterial input function both
of which requirements are not compatible with onco-
logical whole body imaging. For this reason, different
alternative approaches have been investigated in the past
which have tried to facilitate the quantification of Km in
order to make it more suitable for the oncological set-
ting [3-8]. However, none of these approaches have so far
gained widespread acceptance since they either rest on
quite restrictive assumptions and approximations or still
impose demands on data acquisition and evaluation that
are significantly higher than for SUV-based approaches.
Recently, we have shown that a purely image-based quan-
tification of Km might be performed that only requires a
dual time point PET measurement [9]. This seems to con-
stitute the minimum requirement necessary to actually
determine this parameter.While such dual time point pro-
tocols could be considered acceptable for clinical routine,
they still do somewhat increase complexity of the work
flow and data evaluation and will probably only augment
but not replace static oncological imaging.
The SUV approach, on the other hand, has several
known shortcomings [10-12] all of which affect the relia-
bility of the SUV as a surrogate of Km (and the metabolic
rate of glucose consumption). The following are among
these shortcomings:
• Time dependence of the SUV (requiring to strictly
standardize the time point after injection chosen for
imaging and evaluation),
• Susceptibility to errors in scanner calibration,
• Insufficient correlation between systemic distribution
volume and body weight (leading to variants of the
SUV approach using lean body mass (SUVlbm) [13] or
body surface area (SUVbsa) [14] for normalization),
and, consequentially, residual inter-study variability
of the arterial input function (AIF) despite SUV
normalization.
Especially the latter point turns out to be a crucial factor
adversely affecting the correlation between SUV and Km
and, more generally, leading to uncontrolled inter-study
variability of tumor SUVs.
In this work, we propose to replace tumor SUVs by the
tumor-to-blood uptake ratio, called standard uptake ratio
(SUR), in the following: SUR can be expected on theoret-
ical grounds to exhibit a much better linear correlation to
Km than SUV. The derivation for this prediction is given
and evaluated in a group of nine patients with liver metas-
tases of colorectal cancer for which 15 fully dynamical
investigations were available andKm could thus be derived
from conventional Patlak analysis.
Methods
Theory








where Km is the metabolic trapping rate and Vr is the so-
called apparent volume of distribution. This equation is
valid for times later than some time point t∗ (typically t∗ ≈
15 to 20 min post injection (p.i.)).
This equation is of course valid independent of the units
chosen to specify the tracer concentrations, but in the
following we view ct(t), ca(t) as being expressed in SUV
units.
For the sake of argument, we further assume the
following:
1. All input functions exhibit a common shape ba(t),
i.e., are approximately shape invariant across all
considered investigations and only differ by an
investigation-specific scaling factor N: ca(t) ≈
N × ba(t) where N is measured in the same units as
ca and the shape function ba(t) is dimensionless.
Taking into account that all SUV-based evaluations
require that the measurement time is strictly
standardized and denoting this fixed time point as T,
we choose the arbitrary normalization of ba(t) in
such a way that ba(T) = 1. The scaling factor N then
becomes identical to the blood concentration at the
chosen time point: N = ca(T).
2. Variability of the apparent volume of distribution, Vr ,
is small for the considered tumor entity across all
considered investigations, and it can thus be taken to
be approximately constant: Vr ≈ V¯r = const.
It then follows immediately from Equation 1 that the
tumor-to-blood uptake ratio at time t = T is related to the
metabolic rate Km according to
ct(T)
ca(T)
= SUR(T) ≈ (T) × Km + V¯r (2)
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Obviously,  is identical to the independent (x-) coor-
dinate of the Patlak plot which dimensionally is a time
(sometimes called ‘Patlak’s funny time’). The crucial point
here is to realize that  is not influenced by scale changes
of ca(t). If ba(t) can be assumed to have a fixed shape
(at least for ‘most of the time’: shape variations during
the bolus passage do not sizably influence the integral
up to the late time point T), (T) is in fact constant
across all considered investigations for any given choice
of the measurement time point T. The above equations
show that if the used assumptions are adequate, one can
expect a linear relation between SUR and Km (in order
to improve readability, any dependence on T is no longer
stated explicitly here and in the following but has to be
kept in mind).
Contrary to SUR, the tissue SUV itself (i.e., ct) would
only be related linearly to Km if the input functions - when
expressed in SUV units - were in fact completely identical
instead of only shape invariant across different investiga-
tions and target structures. This is directly obvious from
Equation 2 when multiplying both sides by ca:
ct = SUV ≈ AUC × Km + V¯r × ca (4)
since now, both ca and the area under the input curve
would be required to assume investigation-independent
fixed values. This trivially is the case for intra-scan com-
parisons of different target structures but not at all for
inter-subject comparisons (or inter-scan comparisons of
the same patient). Actually, ca is known to exhibit substan-
tial variability across scans even when expressed in SUV
units [13].
To summarize, the difference between SUV and SUR
can be stated as follows : SUR is linearly related to Km
under a distinctly weaker assumption (common shape
of input function required) than SUV (identical input
function required).
The prediction following from the above considerations
is very simple: SUR should be a distinctly better surrogate
parameter of Km than the tissue SUV since it is expected
to exhibit a much higher linear correlation to Km. We
have tested this prediction in the present study focusing
on the potentially most relevant case of investigations in
the trunk where ca can be easily derived within the recon-
structed image volumes from a suitable region in either
the aorta or the left ventricle of the heart.
Study sample
Nine male patients with liver metastases of colorectal
cancer were included retrospectively (age, 48 to 76 years
(mean 62.8); weight, 73 to 100 kg (mean 85.5)). For each
patient, one to three dynamic PET scans of 60min in dura-
tion were performed (altogether 15 scans). Scans started
immediately after injection of 346 to 430 MBq FDG
administrated as bolus over 10 to 20 s. Diabetics were
excluded, and no forced diuresis was used. The scans were
conducted with an ECAT EXACT HR+ (Siemens/CTI,
Knoxville, TN, USA). The acquired data were sorted into
23 to 31 frames with 10 to 20 s in duration during bolus
passage, 30 to 150 s in duration until 10 min p.i., and 300 s
in duration afterwards. Tomographic images were recon-
structed using attenuation weighted OSEM reconstruc-
tion (six iterations, 16 subsets, 6-mm FWHM Gaussian
filter).
The study protocol has been approved by the local
Clinical Institutional Review Board and has complied with
the Declaration of Helsinki.
Data evaluation
The AIF was determined from a roughly cylindrical three-
dimensional (3D) region of interest (ROI) centered in
the aorta. To exclude partial volume effects, a concentric
safety margin of at least 1 cm was used in the transax-
ial plane. To compensate for the resulting small transaxial
diameter, the ROIs were extended axially (along the aorta)
for about 10 cm. This resulted in sufficiently large ROI
volumes (mean ± standard deviation 7.3 ± 1.8 cm3) and
ensured sufficiently high statistical accuracy of the derived
AIF values.
Three-dimensional ROIs were defined in 22 lesions, and
the respective tissue response functions were computed.
ROI definition was performed using the ROVER software
(ABX, Radeberg, Germany; [15,16]). Further data anal-
ysis was carried out using the R software for statistical
computing [17].
For all 22 lesions, Km was derived from conventional
Patlak analysis of the full dynamic data later than 20 min
p.i. (at which time, all Patlak plots were already linear).
The summed late time data between 50 and 60 min p.i.
(corresponding to T = 55 min) were used to determine
ca and ct . For each ROI mean values of SUV (= ct), SUR
(= ct/ca) and Km were computed. Linear regression anal-
ysis was performed for SUV vs. Km and SUR vs. Km,
respectively.
The inter-study variability of ca was determined in SUV
units (SUVa), SUVlbm units (SUValbm), and SUVbsa units
(SUVabsa), respectively. For better comparability, SUVabsa
was normalized such that the mean SUVabsa equals the
mean SUValbm as described in [18]. Additionally, the vari-
ability of area under the curve (AUC) and of  = AUC/ca
was investigated.




Figure 1 shows the complete time course of, both the AIF -
normalized to the time-average of the respective curve,
c¯a = 1T
∫ T
0 ca(s)ds - and (t). As can be seen, the nor-
malized AIFs exhibit only a very small variability beyond
t ≈ 1 min, demonstrating that the assumption of approx-
imate shape invariance is valid. Consequently, inter-study
variability of (t) is small, too. This is especially true
at late times which are the relevant ones in the present
context.
In Figure 2, the inter-study variability of ca is investi-
gated in detail for the chosen time point T = 55 min.
The degree of variability is not reduced when using either
SUVlbm (Figure 2B) or SUVbsa (Figure 2C) instead of
conventional (body weight normalized) SUV (Figure 2A):
on average, we obtain ca = 2.59 ± 0.58 (SUV), 1.99 ±
0.43 (SUVlbm), and 1.99 ± 0.42 (SUVbsa), respectively,
corresponding to a standard deviation of 22% to 23% rel-
ative to the respective mean. Moreover, in our patient
group, ca and serum glucose concentration (range 4.8 to
10.3 μmol/ml) were found to be essentially uncorrelated
(r = −0.14,P < 0.65). With the possible exception of sub-
jects 2 and 6, it can also be observed that the intra-subject
variability is of the same order of magnitude than the
inter-subject variability.
Figure 3 compares the variability of ca at T = 55 min
with that of AUC and . Variability of AUC closely fol-
lows that of ca (which can be understood as a direct
consequence of approximate shape invariance of ca across
investigations) and amounts to a standard deviation of
20%. Due to the highly correlated variations of ca and
AUC,  = AUC/ca exhibits a much smaller variability
with a standard deviation of only 3.2% which demon-
strates that  actually is approximately constant across all
conducted investigations.
Figure 4 shows the correlation between Km and, respec-
tively, SUV (Figure 4A) and SUR (Figure 4B) together with
straight-line fits to the data.
There is only a rather weak correlation between Km and
SUV (r = 0.61) while Km and SUR are strongly correlated
(r = 0.98). The axis intercept of the straight-line fit in the
latter case is a = 0.69 ± 0.10 which compares reason-
ably well with the average apparent volume of distribution
in this patient group (as a result of the Patlak analysis) of
0.53 ± 0.11. The slope is m = 76.8 ± 3.7 min which, too,
is in accord with the theoretical expectation m ≈  and
with Figure 3C from which an average of 82.9 ± 2.6 min
follows for .
Discussion
We could demonstrate a very high linear correlation
between SUR and Km in the investigated patient group
which is in marked contrast to the rather poor lin-
ear correlation between SUV and Km. In fact, the latter
correlation is somewhat inferior to results reported in
the literature (e.g., [5,19]) which might be traced back
to the occurrence of several unusual high ca values
A B
Figure 1 Inter-study variability of AIF shape and(t) = AUC(t)/ca(t) in the available 15 data sets. The thick red lines represent the
group-averaged curves. (A) AIF normalized to the mean value (time-average) of the respective curve. As can be seen, the shape of all AIF curves is
very similar beyond t ≈ 1 min. (B)(t), the ratio of the AUC up to time t divided by ca(t), exhibits only small inter-study variability. Averaging the last
two points of these curves (acquisition time from 50 to 60 min p.i.) yields the data presented in more detail below.
































































Figure 2 Inter-study variability of ca (55min p.i.) in nine subjects
and 15 scans expressed in three SUV units. (A) Conventional SUV
(body weight normalized), (B) SUVlbm (lean body mass normalized),
and (C) SUVbsa (body surface area normalized).
corresponding to the data points exhibiting the largest
deviation from the regression line. This finding might hint
at unidentified problems such as erroneous scanner cal-
ibration at the time of the respective scans although a
retrospective investigation did not reveal any proof for
this. Incidentally, this also demonstrates the insensitivity
of SUR to such possible sources of errors. However, even
when taking the literature values as reference instead of
our own results, it is still true that the degree of linear cor-
relation between SUR and Km is distinctly higher than is
the case when using SUV.
In theoretical terms, the linear SUR vs. Km correla-
tion can be understood as a consequence of a common
input function shape and small variability of the appar-
ent volume of distribution, Vr . The latter was already
demonstrated and discussed in [9].
The former requirement, namely the approximate shape




Figure 3 Inter-study variability of ca and of the corresponding
AUC. (A) Using SUV units in nine subjects and 15 scans and (B) the
corresponding AUC as well as (C)  = AUC/ca at 55 min p.i.
the other hand, is well known to be reasonably well ful-
filled. This has already been utilized in the past, e.g., in the
context of population-averaged input curves ([5,7]). For
completeness, it might also be noted that, in fact, all shape
variations leaving the integral
∫ T
0 ba(s)ds unchanged do
not influence the SUR vs. Km correlation. Strictly speak-
ing, it is not really the shape invariance of the input
function that has to be assumed but only the invari-
ance of the area under the normalized input curve ba(t)
up to time t = T . Notably, this implies that the fre-
quently observed inter-study variability of the AIF during
the early (bolus passage) phase has essentially no influ-
ence since it does not contribute much to the integral
up to T (see Figure 1). Overall, the actually observed
deviations of SUR from the regression line in Figure 4B
directly reflect the (quite small) cumulative effect of
both Vr and input function shape variability in this
patient group.
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Figure 4 Correlation betweenKm and, respectively, lesion SUV (A) and SUR (B) determined at 55 min p.i. Dashed lines represent the
least-squares straight-line fits to the data.
Contrary to SUV determination, the SUR approach
requires delineation of a second ROI to derive the AIF
concentration. This could be seen as an additional source
of inter-observer variability and thus constitute a poten-
tial disadvantage of the approach in comparison with the
SUV usage. While this is true in principle, determination
of the arterial concentration does actually contribute only
modestly to the observed variability of the SUR vs. Km
correlation (which is quite small, anyway). This was veri-
fied by repeated, intentionally differing delineations of the
corresponding 3D ROI. As long as the prescription to use
a substantial safety margin in the transaxial plane and a
reasonable large ROI volume (extending the ROI over a
sufficiently large axial section of the aorta) is respected,
the reproducibility of the results is very high.
As is well known, target to reference tissue ratios have
been frequently used successfully in SPECT as well as in
PET (and still are), e.g. in neuro-receptor imaging, but also
in oncology. In view of this fact, it is somewhat surprising
that seemingly, SUR has up to now not been investigated
systematically as an alternative to SUV in oncological
PET. We were only able to locate a single study explicitly
comparing prognostic parameters derived from tumor-
to-blood ratios and SUVs, respectively, in patients with
non-small cell lung cancer but without comparing these
parameters to Km [20]. The authors reported superiority
of tumor-to-blood ratios over SUV in this study without
further investigating the reason for this finding. Other-
wise, there is only a single methodological work we know
of, namely that by Hunter et al. [5], which proposes a strat-
egy that bears some resemblance to the SUR approach.
These authors used a control-group averaged input func-
tion (modeled as a sum of three exponentials) plus single
venous sampling to fix the unknown amplitudes of the
exponentials. By far, the most important contribution to
the time integral over the input function stems from
the slowest exponential, and the described procedure
therefore essentially reduces to using an invariant-shaped
input function scaled to the actually observed individ-
ual late tracer concentration in the blood. The scaled
input function is then integrated analytically (using the
sum of exponential models) and a formula for Km (called
P2 in that paper) derived that is essentially equivalent
to our Equation 2. Finally, these authors propose to use
ct/AUC for Km estimation, thus neglecting the influence
of the term proportional to Vr in Equation 4 completely.
Hunter et al. were nevertheless able to demonstrate that
the resulting Km estimate correlates highly with true Km
(r = 0.98 and r = 0.97) while SUV (called DUR in that
paper) is found to exhibit a rather unsatisfactory corre-
lation to Km (r = 0.73 and r = 0.84). These findings
are in full accord with those of the present investiga-
tion. The main difference to our work is that Hunter et
al. impose the requirement of a suitable control group
averaged and analytically modeled input curve plus a sin-
gle blood sample in order to estimate the individual area
under the input curve. This knowledge is necessary in
order to estimate Km in their approach. However, the
implied assumption is that  =AUC/ca is constant across
investigations so that, due to the neglect of the small
Vr-dependent term, SUR becomes approximately propor-
tional to Km. While these conclusions are implied in the
work of Hunter et al., they are not explicitly stated or uti-
lized in their work. The present work, on the other hand,
demonstrates that there is no need for either a population-
averaged AIF (and assumption of a specific shape of the
individual AIFs) or blood sampling in order to derive
a quantity (SUR) that is linearly correlated to Km. We
believe this very distinct linear correlation to be the practi-
cally most relevant aspect. Whether conversion from SUR
to Km does always make sense is not so obvious as will be
discussed below.
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Compared to tissue SUV, the use of SUR eliminates
a couple of shortcomings of the former. For one, SUR
is a dimensionless quantity that is neither affected by
inaccuracies of scanner or dose calibration nor by erro-
neous body weight (or related quantities). While this
is clearly advantageous, the most relevant improve-
ment of SUR over SUV in our view is elimination of
a very large part of the variability caused by inter-
scan variations of the input function. Given the empir-
ically well demonstrated approximately invariant shape
of FDG input functions, SUR eliminates the influence
of inter-scan variations of tracer supply nearly com-
pletely. Quite to the contrary, variations in the scale
of ca(t) (if measured in SUV units) directly translate
into substantial SUV changes. As Figure 2 demonstrates,
the inter-subject as well as the intra-subject variabil-
ity of ca is indeed substantial (exhibiting a standard
deviation of about 23% from the mean) which directly
explains the large fluctuations of the SUVs observed
in Figure 4A. It should be stressed, that this variabil-
ity of ca persists after conversion to SUV units (or to
SUVlbm or SUVbsa, for that matter). In other words,
the central objective of SUV-based approaches, namely
correction for variations of injected dose and systemic
distribution volume of the tracer, is not achieved sat-
isfactorily. Consequently, comparing SUV values across
investigations makes only limited sense and is prone to
potentially serious errors if the objective is to assess
changes of glucose metabolism. Inter-study compari-
son of SUR values appears much more reasonable in
this respect. At least since the advent of PET/CT a
purely image-based determination of the blood signal
from a large vessel is straightforward even where this
would not be quite as easy when using the whole
body PET data alone. Therefore, SUR computation does
especially not require any blood sampling and could
also easily be performed retrospectively using existing
data for systematic performance comparisons of SUV
and SUR.
As demonstrated, replacing SUVs by SURs does elim-
inate some important sources of SUV-specific system-
atic errors which leads to a very good linear correlation
between SUR and Km. On the other hand, this does
not imply that SURs are necessarily also suitable for
quantitative determination of Km in general since the
SUR vs. Km correlation shown in Figure 4B need not
be universally valid for two reasons. First, according to
Equation 3, the slope of the SUR (Km) correlation is
identical to the integral over ba(t) up to t = T . Differ-
ent injection protocols (duration of injection, bolus vs.
ramp etc.) naturally will thus lead to a different (and
unknown) slope parameter. However, even if the invari-
ant shape assumption can be considered universally valid,
the slope remains a function of T and thus will change
(in an unknown way) if the time of measurement is
changed.
Second, the intercept of the regression line approxi-
mates the average apparent volume of distribution, V¯r ,
and thus might vary across different tumor entities and
tissues. We believe this probably to be a small effect
for most tumors and healthy tissues (although this can-
not be taken for granted and would need to be proven
by further investigations), but for certain tissues and
when inflammation is involved (i.e., if the assumption
of irreversible trapping is not fulfilled), larger varia-
tions of Vr will occur, and consequently, the relation
between SUR and Km will be distinctly modified. Obvi-
ously, the presence of a sizable dephosphorylation (i.e.,
a sizable k4 in the corresponding two-compartment
model) would actually invalidate the prediction of a lin-
ear SUR vs. Km correlation completely. It should be
noted, however, that this is not a specific problem of
the SUR approach but affects SUV evaluations accord-
ingly. In the present study, inspection of the Patlak
plots unambiguously demonstrated that the FDG kinet-
ics in the liver lesions is compatible with the assumption
k4 = 0.
Still, in general, it cannot be expected that the regres-
sion line in Figure 4B is universally valid (at least not with
good accuracy), and quantitative conversion of SUR to Km
should probably be avoided in our view (and would not
offer additional benefits).
Instead, we surmise that it might be worthwhile to com-
bine the SUR approach with a dual time point-based
determination of Km [9] in order to identify regions in
which the SUR vs. Km relation is changed. This possi-
bly could, e.g., enable a more sensitive identification of
inflammatory processes than is possible with dual time
point measurements alone.
Where such dual time point protocols allowing for inde-
pendent determination of Km and SUR are considered
not compatible with the requirements of clinical routine,
SUR alone still offers distinct advantages over SUV-based
approaches because a good linear correlation to Km sim-
ilar to that shown in Figure 4B can be expected in most
tissues and target structures (i.e., those where FDG kinet-
ics can be considered to be irreversible): a fractional
change of SUR will in general correspond to a concomi-
tant change of Km where even modest SUR changes will
be meaningful due to the very high degree of linear corre-
lation of both quantities (as long as a sufficiently accurate
determination of ca within the image data is performed
that avoids partial volume and spill over effects). Inter-
study SUV differences, instead, are likely to be partially or
even completely spurious (i.e., unrelated to Km changes)
due to the insufficient correction for inter-study variabil-
ity of arterial tracer concentration achieved by the SUV
approach.
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Conclusions
The tumor-to-blood standard uptake ratio, SUR exhibits
a much higher linear correlation to the metabolic rate of
FDG, Km, than tumor SUV (or SUVlbm or SUVbsa). This
improved correlation can be understood theoretically as
a consequence of the approximate shape invariance of
FDG input functions. Purely image-based determination
of SUR is straightforward in whole body investigations
and allows to account for variations in tracer supply across
investigations distinctly better than when using SUVs.
Therefore, SUR should be seriously considered as a drop-
in replacement for SUV-based approaches.
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